A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura

Medical Hypotheses

Volumn 83, Issue 6, 2014, Pages 747-750

  Hoirisch Clapauch, Silvia ^a   Nardi, Antonio Egidio ^b  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD VESSEL WALL; COMORBIDITY; ENZYME ACTIVITY; HUMAN; HYPERCORTISOLISM; HYPERINSULINEMIA; PATHOPHYSIOLOGY; RELAPSE; REMISSION; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; AUTOIMMUNITY; BLOOD; BODY MASS; CUSHING SYNDROME; DEFICIENCY; HYPERINSULINISM; METABOLISM;

ADAM PROTEINS; AUTOIMMUNITY; BLOOD PLATELETS; BODY MASS INDEX; CUSHING SYNDROME; FIBRINOLYSIN; HUMANS; HYPERINSULINISM; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 84918776766     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.09.032     Document Type: Article

References (58)

1. Lämmle B., Hovinga J.A.K., Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005, 3:1663-1675.
2. Sadler J.E., Moake J.L., Miyata T., et al. Recent advances in thrombotic thrombocytopenic purpura. ASH Educ Program Book 2004, 407-423.
3. Fujikawa K., Suzuki H., McMullen B., et al. Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
4. Vesely S.K., George J.N., Lämmle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
5. Tersteeg C., de Maat S., De Meyer S.F., et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 2014, 129:1320-1331.
6. Wohner N., Kovács A., Machovich R., et al. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways. Thromb Res 2012, 129:e41-e46.
7. Shin Y., Akiyama M., Kokame K., et al. Binding of von Willebrand factor cleaving protease ADAMTS13 to Lys-plasmin(ogen). J Biochem 2012, 152:251-258.
8. Bu F., Maga T., Meyer N.C., et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014, 25:55-64.
9. Schuster V., Hugle B., Tefs K. Plasminogen deficiency. J Thromb Haemost 2007, 5:2315-2322.
10. Deford C.C., Reese J.A., Schwartz L.H., et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013, 122:2023-2029.
11. Gruzdeva O.V., Uchasova E.G., Dyleva Y.A., et al. Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction. Eur Heart J 2013, 34:P5498.
12. Cataland S.R., Scully M.A., Paskavitz J., et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2011, 86:87-89.
13. Tauchi R., Imagama S., Ohgomori T., et al. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci Lett 2012, 517:1-6.
14. Benarroch E.E. Tissue plasminogen activator. Beyond thrombolysis. Neurology 2007, 69:799-802.
15. Melchor J.P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005, 93:655-660.
16. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
17. Tsai S.J., Hong C.J., Liou Y.J., et al. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics 2008, 18:869-875.
18. Lu B., Pang P.T., Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005, 6:603-614.
19. Jag U.R., Zavadil J., Stanley F.M. Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1. Mol Endocrinol 2009, 23:1587-1602.
20. Zhu Y., Carmeliet P., Fay W.P. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999, 99:3050-3055.
21. Hodson K., Dalla Man C., Smith F.E., et al. Mechanism of insulin resistance in normal pregnancy. Horm Metab Res 2013, 45:567-571.
22. Ryan E.A., O'Sullivan M.J., Skylar J.S. Insulin action during pregnancy. Studies with the euglycemic clamp technique. Diabetes 1985, 34:380-389.
23. Chawla A., Nguyen K.D., Goh Y.S. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011, 11:738-749.
24. Briones A.M., Cat A.N.D., Callera G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59:1069-1078.
25. Jiang Y., McIntosh J.J., Reese J.A., et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood 2014, 123:1674-1680.
26. Morgan J.A., Bombell S., McGuire W. Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One 2013, 8:e56907.
27. Khamaisi M., Skarzinski G., Mekler J., et al. Hyperinsulinemia increases placenta endothelin-converting enzyme-1 expression in trophoblasts. Am J Hypertens 2012, 25:109-114.
28. Timonen M., Laakso M., Jokelainen J., et al. Insulin resistance and depression: cross sectional study. BMJ 2005, 330:17-18.
29. Taguchi A. Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 2009, 16:859-864.
30. Hlavacova N., Wes P.D., Ondrejcakova M., et al. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2012, 15:247-265.
31. Jeong Y., Chaupin D.F., Matsushita K., et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 2009, 106:3782-3787.
32. Lancellotti S., Filippis V., Pozzi N., et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: a new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010, 48:446-456.
33. Vischer U.M. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006, 4:1186-1193.
34. Norbiato G. Endocrine, metabolic, and immunologic components of HIV infection. Ann N Y Acad Sci 2012, 1262:51-55.
35. Goshen I., Yirmiya R. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009, 30:30-45.
36. Morelli V., Masserini B., Salcuni A.S., et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol 2010, 73:161-166.
37. Ou X.M., Storring J.M., Kushwaha N., et al. Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. J Biol Chem 2001, 276:14299-14307.
38. 1A receptor function in major depressive disorder. Prog Neurobiol 2009, 88:17-31.
39. Erem C., Nuhoglu I., Yilmaz M., et al. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009, 32:169-174.
40. Van der Pas R., De Bruin C., Leebeek F.W.G., et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 2010, 97:1303-1310.
41. Girod J.P., Brotman D.J. Does altered glucocorticoid homeostasis increase cardiovascular risk?. Cardiovasc Res 2004, 64:217-226.
42. Casonato A., Pontara E., Boscaro M., et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis 1999, 10:145-151.
43. Chopra A., Kumar R., Kishore K., et al. Effect of glucocorticoids on von Willebrand factor levels and its correlation with von Willebrand factor gene promoter polymorphism. Blood Coagul Fibrinolysis 2012, 23:514-519.
44. Appenzeller S., Lapa A.T., Guirau C.R., et al. Cognitive impairment in antiphospholipid syndrome: evidence from animal models. Clin Rheumatol 2012, 31:403-406.
45. Krone K.A., Allen K.L., McCrae K.R. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12:53-57.
46. Bertsias G.K., Ioannidis J.P.A., Aringer M., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
47. Cheung W.Y. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus - distinct entities or overlapping syndromes?. Transfus Apher Sci 2006, 34:263-266.
48. Cerveny K.C., Sawitzke A.D. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura?. Lupus 1999, 8:477-481.
49. George J.N. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (experience of the Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int Suppl 2009, 75:S8-S10.
50. Scully M., Hunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012, 158:323-335.
51. Fiaccadori E., Maggiore U., Rotelli C., et al. Thrombotic-thrombocytopenic purpura following malaria prophylaxis with mefloquine. J Antimicrob Chemother 2006, 57:160-161.
52. Yilmaz V.T., Koçak H., Avci A.B., et al. Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol 2011, 43:581-584.
53. White M., Ross H., Haddad H., et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. Transplantation 2006, 82:763-770.
54. Baas M.C., Gerdes V.E., ten Berge I.J., et al. Treatment with everolimus is associated with a procoagulant state. Thromb Res 2013, 132:307-311.
55. Nagaya S., Wada H., Oka K., et al. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol 1995, 50:237-243.
56. Asuthkar S., Stepanova V., Lebedeva T., et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell 2013, 24:2620-2632.
57. Declerck P.J., De Mol M., Alessi M.C., et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988, 263:15454-15461.
58. Raps M., Helmerhorst F.M., Fleischer K., et al. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost 2013, 109:606-613.